Precision Medicine

Genetic tests are booming, but can primary care providers keep up?

92 million accounts may have been exposed in a recent cybersecurity incident. Actually, 92,283,889, to be exact.

The burgeoning gen-editing giant will test its zinc finger nuclease (ZFN) editing technology against lysosomal storage disorders in children.

"An objective, precise, compact, unambiguous, easily-interpretable description of all loops, stems, and pseudoknots."

When offered remote counseling, patients were far more likely to be tested...and to have their potentially-risky variants identified.

After genealogy data was used to make an arrest in the Golden State Killer case, NIH bioethicist Benjamin Berkman had some questions.

Why investors like the company’s high-tech approach to patient outcomes.

One of the world's most-recognized genomic scientists is retiring from the ambitious company that he founded.

The AI and genetics company has been winning competitions and grants at a steady clip this year.

What made Shivom’s secure genome sequencing so tempting to investors?

The company just published new study results about the 6-month cost savings associated with a mental health drug efficacy assay.

A new $6 million funding round led by Triventures could help the company in its efforts to democratize next-generation sequencing technology.

The American Gut Project has inspired more than 10,000 people to mail fecal samples to UC San Diego. That's a good thing.

During an interview at HLTH, CEO Robin Smith said his company had no interest in deciding who else could see a consumer's genetic info.

There's more patient data out there than ever, but big data can create big problems.

From big data’s role in solving coming healthcare problems to Comcast’s new partnership, these stories resonated with our readers.

Genomics has attracted heavy investment in recent years. Will it ever end?

The cable and media giant will launch a pilot project with Independence Health to bring personalized health content and guidance to patients.

SOPHiA Genetics, a Swiss health-tech company, is celebrating a diagnostics milestone and a $1.4 billion windfall for AI overseas.

The funding will support the study of ST-400 as a cell therapy candidate for people with transfusion-dependent beta-thalassemia.

Original research suggests that clinicians want their organizations to better embrace tech surrounding the therapy.

Nearly everyone extols the need to bust data silos. Meet the man who’s doing it.

The publically-accessible repository, built alongside Microsoft and DNAnexus, is meant to spur research and collaboration to fight pediatric cancer.

"Promoting and protecting public health requires FDA to adopt policies to ensure regulation serves as bridge to innovation, not a barrier to it," he tweeted.

The pair want to combine their chemistry and machine learning platforms to find targets for neuromuscular disease treatments.

A new program there is armed with $750,000 in grant funding to look for answers in the assays.

The precision medicine innovator plans to use the money to finance the second generation of the immunotherapies.

Want to make an easy million, or 60? Just develop some proprietary genomics technologies for cancer detection and treatment.

Looking to grow its consumer-facing Health Nucleus platform, the genomics company announced a $25,000 plan that includes MRIs and a battery of other tests.

“People may assume that they are being provided accurate medical grade testing, so understandably do not go to the trouble and expense of seeking confirmation.”